ENCOD
  • News
  • Our Mission
    • About
    • Our Team
    • ENCOD MEMBERS
    • INFO FOR MEMBERS
    • IN THE PRESS
    • FAQ
  • Actions & Events
    • CAMPAIGNS
      • FREEDOM TO FARM
        • FREEDOM TO FARM
        • FREEDOM TO FARM IS THE FIRST TEST OF RELIGIOUS FREEDOM
        • FREEDOM TO FARM AND CANNABIS SOCIAL CLUBS FOR PEOPLE WHO USE CANNABIS AS A MEDICINE
        • FREEDOM TO FARM POSTERS
        • FREEDOM TO FARM STICKERS
      • Cannabis Social Clubs
        • EXAMPLES OF CSC’S IN EUROPE
        • Cannabis Social Clubs in Aktion
        • HOW TO CREATE A CANNABIS SOCIAL CLUB
        • PROPOSAL TO REGULATE THE SELF CULTIVATION AND CANNABIS SOCIAL CLUBS IN BELGIUM
        • Catalonia regulates the Cannabis Social Clubs
        • WORKSHOP ‘HOW TO SET UP A CSC IN GERMANY’
      • 2017
      • 2014
      • 2010 – 2013
      • 2009
      • 2008
      • 2007
      • 2006
      • 1995 – 2005
      • EU LOBBY CAMPAIGN
        • 2011
        • 2010
        • 2009
        • 2008
        • 2007
        • 2006
        • 2005
        • 2004
    • AGENDA
    • EVENTS
    • ACTION APPEALS
  • Organisation
    • The Executive Committee
      • WORKING GROUPS
      • STUDIES
      • GENERAL ASSEMBLIES
      • FINANCES
    • ANNUAL REPORTS
  • Bulletins
  • Films & Videos
  • enEnglish
  • News
  • Our Mission
    • About
    • Our Team
    • ENCOD MEMBERS
    • INFO FOR MEMBERS
    • IN THE PRESS
    • FAQ
  • Actions & Events
    • CAMPAIGNS
      • FREEDOM TO FARM
        • FREEDOM TO FARM
        • FREEDOM TO FARM IS THE FIRST TEST OF RELIGIOUS FREEDOM
        • FREEDOM TO FARM AND CANNABIS SOCIAL CLUBS FOR PEOPLE WHO USE CANNABIS AS A MEDICINE
        • FREEDOM TO FARM POSTERS
        • FREEDOM TO FARM STICKERS
      • Cannabis Social Clubs
        • EXAMPLES OF CSC’S IN EUROPE
        • Cannabis Social Clubs in Aktion
        • HOW TO CREATE A CANNABIS SOCIAL CLUB
        • PROPOSAL TO REGULATE THE SELF CULTIVATION AND CANNABIS SOCIAL CLUBS IN BELGIUM
        • Catalonia regulates the Cannabis Social Clubs
        • WORKSHOP ‘HOW TO SET UP A CSC IN GERMANY’
      • 2017
      • 2014
      • 2010 – 2013
      • 2009
      • 2008
      • 2007
      • 2006
      • 1995 – 2005
      • EU LOBBY CAMPAIGN
        • 2011
        • 2010
        • 2009
        • 2008
        • 2007
        • 2006
        • 2005
        • 2004
    • AGENDA
    • EVENTS
    • ACTION APPEALS
  • Organisation
    • The Executive Committee
      • WORKING GROUPS
      • STUDIES
      • GENERAL ASSEMBLIES
      • FINANCES
    • ANNUAL REPORTS
  • Bulletins
  • Films & Videos
  • enEnglish
January 15, 2016  |  By ENCOD In 2016

Drug trial was not based on cannabis, but media reports are

arton5621

15 January 2016

So in the end it appears to be an effort to imitate the effects of cannabis. Because cannabis itself has to remain illegal, of course, as otherwise it would be the Pharmafia that would suffer great financial pain. Meanwhile nobody has ever died from using the plant, and hundreds of millions of people benefit from it. But that does not make the newspapers.


PARIS — One man is brain dead and three others are facing possible permanent brain damage after volunteering to take part in a botched drug test in western France, the French Health Ministry said Friday.

The prosecutor’s office has opened an investigation into what French Health Minister Marisol Touraine called “an accident of exceptional gravity” at the private Biotrial clinical lab in Rennes.

The drug trial, which was testing a new painkiller compound, involved 90 healthy volunteers who were given the experimental drug in varying doses beginning on Jan. 7, she told reporters Friday at a news conference in Rennes.

Six male volunteers between 28 and 49 years old have since been hospitalized, including one man now classified as brain dead, she said.

The chief neuroscientist at the hospital in Rennes, Professor Gilles Edan, said in addition to the brain-dead volunteer, three others could have “irreversible” brain damage. A fifth man is suffering from neurological problems and a sixth volunteer is being kept in the hospital but is in a less critical condition, he said.

Edan said there’s no known treatment for the experimental drug that Biotrial was testing. The drug was a based on a natural brain compound similar to the active ingredient in marijuana.

Touraine said the medication was not based on cannabis, as some media reports had claimed. She urged calm, saying that no drug currently on the market was implicated in the failed trial. She said the drug was produced by the Portuguese pharmaceutical company Bial, which said Friday it had no comment on the failed trial at this time.

All the other 83 volunteers are being contacted, Touraine said.

It’s rare for volunteers to fall seriously ill when testing new drugs. Researchers generally start with the lowest possible dose for humans after extensive drug tests in animals. The French ministry statement said those who had fallen ill had taken an oral medication in the first phase of testing, which was studying safe usage, tolerance and other measures on healthy volunteers.

Biotrial, with headquarters in Rennes and offices in London and Newark, New Jersey, says it has over 25 years of experience in clinical trials and uses “state-of-the-art facilities.” In France, adults volunteering for Biotrial tests can earn between 100 euros and 4,500 euros ($110 to $4,922).

In 2006, Britain saw a similar incident, when six previously healthy men were treated for organ failure only hours after being given an experimental drug targeting the immune system. That prompted a review of procedures and resulted in the U.K. regulatory agency imposing new testing standards, including recommendations to use the lowest possible dose and to test new drugs only in one person at a time.

The six men in Britain now apparently have a higher risk of cancer and autoimmune diseases tied to their exposure to the experimental drug.

Dr. Ben Whalley, a neuropharmacology professor at Britain’s University of Reading, said standardized regulations for clinical trials are “largely the same” across Europe.

“However, like any safeguard, these minimize risk rather than abolish it,” Whalley said in a statement. “There is an inherent risk in exposing people to any new compound.”


—Elaine Ganley, Thomas Adamson, Maria Cheng

Creative Commons License AttributionRepublish
Previous StoryRueda de prensa de Pannagh
Next StoryThis drug does not contain cannabis

Related Articles

  • ibogaine-treatment.jpg
    Are Italy and the American DEA out to ban effective heroin detox?
  • weed-made-in-italy.png
    Encod and the Italian Draft of the Parliamentary Intergroup Legal cannabis

Recent posts

  • ENCOD General Assembly 2018 Press Release
  • Survey: European Civil Society on Drugs Report (ENCOD)
  • ENCOD General Assembly 2018
  • Welcome to the new ENCOD website!
  • ENCOD Bulletin 147: Thoughts for societies that use drugs.

Recent Comments

  • encod on A response to Bushka Bryndova’s letter to president Putin
  • encod on A response to Bushka Bryndova’s letter to president Putin
  • cureall on THE BEST WAY TO PRODUCE CANNABIS OIL
  • Michelle on 700 MEDICINAL USES OF CANNABIS SORTED BY DISEASE
  • encod on The demons in drug law reform: A critical look at regulation and stigma

Categories

Archives

Encod Gold Member

Sensi Seeds

Copyright ©2018 ENCOD. All Rights Reserved

  • enEnglish
×

REPUBLISHING TERMS

You may republish this article online or in print under our Creative Commons license.
You may not edit or shorten the text and you must attribute the article to ENCOD (www.encod.org) plus you must include the author’s name in your republication.

If you have any questions, please email [email protected]

License

Creative Commons License AttributionCreative Commons Attribution
Drug trial was not based on cannabis, but media reports are